Literature DB >> 9054386

Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor.

J F Maddox1, M Hachicha, T Takano, N A Petasis, V V Fokin, C N Serhan.   

Abstract

Lipoxins (LX) are bioactive eicosanoids that activate human monocytes and inhibit neutrophils. LXA4 is rapidly converted by monocytes to inactive products, and to resist metabolism, synthetic analogs of LXA4 were designed. Here, we examined the bioactivity of several LXA4 analogs in monocytes and found, for chemotaxis, 15(R/S)-methyl-LXA4 and 15-epi-LXA4 were equal in activity, and 16-phenoxy-LXA4 was more potent than native LXA4. Both 15(R/S)-methyl-LXA4 and 16-phenoxy-LXA4 were approximately 1 log molar more potent than LXA4 in stimulating THP-1 cell adherence (EC50 approximately 1 x 10(-10) M). Dimethylamide derivatives of the LXA4 analogs also possessed agonist rather than antagonist properties for monocytes. Neither LXA4 nor 16-phenoxy-LXA4 affected monocyte-mediated cytotoxicity. We cloned an LXA4 receptor from THP-1 cells identical to that found in PMN. Evidence of receptor-mediated function of LXA4 and the stable analogs in monocytes included desensitization of intracellular calcium mobilization to a second challenge by equimolar concentrations of these analogs, but not to LTB4. Increases in [Ca2+]i by LXA4 and the analogs were specifically inhibited by an antipeptide antibody to the LXA4 receptor; and both LXA4- and analog-induced adherence and increments in Ca2+ were sensitive to pertussis toxin. Together, these results indicate that the LXA4 stable analogs are potent monocyte chemoattractants and are more potent than native LXA4 in stimulating THP-1 cell adherence, at subnanomolar concentrations. Moreover, they provide additional evidence that the LXA4 stable analogs retain selective bioactivity in monocytes and are valuable instruments for examining the functions and modes of action of LXA4.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9054386     DOI: 10.1074/jbc.272.11.6972

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  91 in total

Review 1.  Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology.

Authors:  Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-03

Review 2.  Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus.

Authors:  C N Serhan; N Chiang
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 3.  Anti-inflammatory and proresolving lipid mediators.

Authors:  Charles N Serhan; Stephanie Yacoubian; Rong Yang
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

Review 4.  Phagocyte partnership during the onset and resolution of inflammation.

Authors:  Oliver Soehnlein; Lennart Lindbom
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

Review 5.  Inflammatory and immune pathways in the pathogenesis of periodontal disease.

Authors:  Ali Cekici; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

6.  Role of Major Toxin Virulence Factors in Pertussis Infection and Disease Pathogenesis.

Authors:  Karen Scanlon; Ciaran Skerry; Nicholas Carbonetti
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 7.  A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution.

Authors:  Charles N Serhan
Journal:  Histochem Cell Biol       Date:  2004-08-21       Impact factor: 4.304

Review 8.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

9.  Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis.

Authors:  Mingqin Zhu; Xiuzhe Wang; Erik Hjorth; Romain A Colas; Lisa Schroeder; Ann-Charlotte Granholm; Charles N Serhan; Marianne Schultzberg
Journal:  Mol Neurobiol       Date:  2015-12-09       Impact factor: 5.590

10.  A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor.

Authors:  Aram Elagoz; Duncan Henderson; Poda Suresh Babu; Sylvia Salter; Caroline Grahames; Lorna Bowers; Marie-Odile Roy; Patricia Laplante; Eric Grazzini; Sultan Ahmad; Paola M C Lembo
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.